| Andrew W Yetter, MD | |
|
5300 Memorial Dr, Two Rivers, WI 54241-3923 | |
| (920) 793-7300 | |
| Not Available |
| Full Name | Andrew W Yetter |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 34 Years |
| Location | 5300 Memorial Dr, Two Rivers, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578586368 | NPI | - | NPPES |
| 32219800 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 37746 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Sheboygan Memorial Medical Ctr | Sheboygan, WI | Hospital |
| Aurora Medical Ctr Manitowoc County | Two rivers, WI | Hospital |
| Aurora Baycare Medical Ctr | Green bay, WI | Hospital |
| Holy Family Memorial | Manitowoc, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Health Care Central, Inc. | 4688583677 | 6 |
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
More than 65 million people, or 29 percent of the U.S. population, provide care for a chronically ill, disabled or aged family members or friends during any given year, and spend an average of 20 hours per week providing that care.
Two new studies available online and being published in the April edition of the American Journal of Preventative Medicine find that electronic cigarettes produces abstinence rates nearly double that of traditional nicotine replacement methods and that consumer interest in e-cigarettes is currently much higher than interest in traditional nicotine replacement products.
Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.
› Verified 9 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
More than 65 million people, or 29 percent of the U.S. population, provide care for a chronically ill, disabled or aged family members or friends during any given year, and spend an average of 20 hours per week providing that care.
Two new studies available online and being published in the April edition of the American Journal of Preventative Medicine find that electronic cigarettes produces abstinence rates nearly double that of traditional nicotine replacement methods and that consumer interest in e-cigarettes is currently much higher than interest in traditional nicotine replacement products.
Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.
› Verified 9 days ago
| Entity Name | Aurora Health Care North Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477508687 PECOS PAC ID: 9436067402 Enrollment ID: O20040211000368 |
News Archive
More than 65 million people, or 29 percent of the U.S. population, provide care for a chronically ill, disabled or aged family members or friends during any given year, and spend an average of 20 hours per week providing that care.
Two new studies available online and being published in the April edition of the American Journal of Preventative Medicine find that electronic cigarettes produces abstinence rates nearly double that of traditional nicotine replacement methods and that consumer interest in e-cigarettes is currently much higher than interest in traditional nicotine replacement products.
Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.
› Verified 9 days ago
| Entity Name | Aurora Health Care Central, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922053107 PECOS PAC ID: 4688583677 Enrollment ID: O20040308000588 |
News Archive
More than 65 million people, or 29 percent of the U.S. population, provide care for a chronically ill, disabled or aged family members or friends during any given year, and spend an average of 20 hours per week providing that care.
Two new studies available online and being published in the April edition of the American Journal of Preventative Medicine find that electronic cigarettes produces abstinence rates nearly double that of traditional nicotine replacement methods and that consumer interest in e-cigarettes is currently much higher than interest in traditional nicotine replacement products.
Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew W Yetter, MD Po Box 735044, Chicago, IL 60673-5044 Ph: (920) 793-6100 | Andrew W Yetter, MD 5300 Memorial Dr, Two Rivers, WI 54241-3923 Ph: (920) 793-7300 |
News Archive
More than 65 million people, or 29 percent of the U.S. population, provide care for a chronically ill, disabled or aged family members or friends during any given year, and spend an average of 20 hours per week providing that care.
Two new studies available online and being published in the April edition of the American Journal of Preventative Medicine find that electronic cigarettes produces abstinence rates nearly double that of traditional nicotine replacement methods and that consumer interest in e-cigarettes is currently much higher than interest in traditional nicotine replacement products.
Scientists at GE Global Research, and researchers at Eli Lilly and Company today announced a significant advancement in cancer research resulting from the two companies' collaboration formed in October 2007.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.
› Verified 9 days ago
Dr. Cedric V Thayer, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2219 Garfield St, Two Rivers, WI 54241 Phone: 920-793-2281 Fax: 920-794-7553 | |
Brian P Laliberte, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2219 Garfield St, Two Rivers, WI 54241 Phone: 920-793-2281 | |
Samuel Quinn Ballard, DO Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 800 Lakefront Way, Two Rivers, WI 54241 Phone: 920-320-2436 | |
Dr. Dale Edwin Asche, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 900 17th St, Two Rivers, WI 54241 Phone: 920-242-7202 | |
Matthew J Hobbins, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5000 Memorial Dr, Two Rivers, WI 54241 Phone: 920-794-5000 | |
Dr. Barbara J Gonzales, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5000 Memorial Dr, Two Rivers, WI 54241 Phone: 920-794-5000 |